Dihydrocodeine as an opioid analgesic for the treatment of moderate to severe chronic pain

Current Drug Metabolism

Volumn 11, Issue 6, 2010, Pages 494-506

  Leppert, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Analgesia; Analgesic; Analgesic effects; Cancer pain; Chronic pain; Dihydrocodeine; Opioids

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CHLORPHENIRAMINE; CODEINE; CODYDRAMOL; DIHYDROCODEINE; DIHYDROCODEINE 6 GLUCURONIDE; DIHYDROMORPHINE; DIHYDROMORPHINE 3 GLUCURONIDE; FENTANYL; HYDROMORPHONE; LAXATIVE; METHADONE; METHYLEPHEDRINE; MORPHINE; NALOXONE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROCODEINE; NOSCAPINE; OXYCODONE; PARACETAMOL; PETHIDINE; PLACEBO; SILDENAFIL; STEROID; TRAMADOL; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ANALGESIA; ARTHRALGIA; BACKACHE; BLOOD PRESSURE; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; CREATININE CLEARANCE; DIZZINESS; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVITY; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INSOMNIA; MALAISE; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PHARMACODYNAMICS; POLYARTHRITIS; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; SKIN TINGLING; URINE RETENTION; URINE VOLUME; VERTIGO; VISCERAL PAIN; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; ANIMALS; CHRONIC DISEASE; CODEINE; HUMANS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 77954156991     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791636211     Document Type: Review

References (56)

1. Gravenstein, J.S.; Smith, G.M.; Sphire, R.D.; Isaacs, J.P.; Beecher, H.K. Dihydrocodeine. N. Engl. J. Med., 1956, 254, 877-885.
2. Keats, A.S.; Telford, J.; Kurosu, Y. Studies of analgesic drugs: Dihydrocodeine. J. Pharmacol. Exp. Ther., 1957, 120, 354-360.
3. Robertson, J.R. Dihydrocodeine: second strand of treatment for drug misusers. Drug. Alcohol. Rev., 1996, 15, 200-201.
4. Ammon, S.; Hofmann, U.; Griese, E.U.; Gugeler, N.; Mikus, G. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br. J. Clin. Pharmacol., 1999, 48, 317-322.
5. Twycross, R. Weak opioids. In Pain Relief in Advanced Cancer Twycross, R.; Ed. Churchill Livingstone: Edinburgh, 1994; pp. 233-254.
6. Rowell, F.J.; Seymour, R.A.; Rawlins, M.D. Pharmacokinetics of Intravenous and Oral Dihydrocodeine and its Acid Metabolites. Eur. J. Clin. Pharmacol., 1983, 25, 419-424.
7. Frazer, N.M.; Galloway, D.B.; Lockwood, G. F.; McKeller, J.; Quinn, K.G. Single- and multiple-dose pharmacokinetic studies of DHC Continus tablets 60 mg, a novel dihydrocodeine preparation. 1986 International Symposium on Pain Control; Doyle, D.; Ed.; Royal Society of Medicine Services International Congress and Symposium Series No 123, published by Royal Society of Medicine Services Limited, 1987; pp. 101-107.
8. Schmidt, H.; Vormfelde, S.V.; Walchner-Bonjean, M.; Klinder, K.; Freudenthaler, S.; Gleiter, C.H.; Gundert-Remy, U.; Skopp, G.; Aderjan, R.; Fuhr, U. The role of active metabolites in dihydrocodeine effects. Int. J. Clin. Pharmacol. Ther., 2003, 41, 95-106. (Pubitemid 36348269)
9. Fromm, M.F.; Hofmann, U.; Griese, E.U.; Mikus, G. Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans. Clin. Pharmacol. Ther., 1995, 58, 374-382.
10. Schmidt, H.; Vormfelde, S.V.; Klinder, K.; Gundert-Remy, U.; Gleiter, C.H.; Skopp, G.; Aderjan, R.; Fuhr, U. Affinities of Dihydrocodeine and its Metabolites to Opioid Receptors. Pharmacol. Toxicol., 2002, 91, 57-63.
11. Webb, J.A.; Rostami-Hodjegan, A.; Abdul-Manap, R.; Hofmann, U.; Mikus, G.; Kamali, F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br. J. Clin. Pharmacol., 2001, 52, 35-43. (Pubitemid 32862767)
12. Jurna, I.; Kömen, W.; Baldauf, J.; Fleischer, W. Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus. J. Pharmacol. Exp. Ther., 1997, 281, 1164-1170. (Pubitemid 27258373)
13. Wilder-Smith, C.H.; Hufschmid, E.; Thormann, W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor matabolizers. Br. J. Clin. Pharmacol., 1998, 45, 575-581.
14. Kirkwood, L.C.; Nation, R.L.; Somogyi, A.A. Characterization of the human cytochrome P450 enzyme involved in the metabolism of dihydrocodeine. Br. J. Clin. Pharmacol., 1997, 44, 549-555. (Pubitemid 27517481)
15. Kirkwood, L.C.; Nation, R.L.; Somogyi, A.A. Glucuronidation of Dihydrocodeine by Human Liver Microsomes and the Effect of Inhibitors. Clin. Exp. Pharmacol. Physiol., 1998, 25, 266-270.
16. Wilder-Smith, C.H.; Hill, L.; Spargo, K.; Kalla, A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomized study comparing analgesia, antinociception and gastrointestinal effects. Pain, 2001, 91, 23-31.
17. Moore, R.A., McQuay, H.J. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain, 1997, 69, 287-294.
18. Edwards, J.E.; McQuay, H.J.; Moore, R.A. Combination Analgesic Efficacy: Individual Patient Data Meta-Analysis of Single-Dose Oral Tramadol Plus Acetaminophen in Acute Postoperative Pain. J. Pain. Symptom. Manage., 2002, 23, 121-130.
19. Moore, R.A.; Collins, L.; Carroll, D.; McQuay, H. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain, 1997, 70, 193-201.
20. De Craen, A.J.M.; Di Giulio, G.; Lampe-Schoenmaeckers, A.J.E.M.; Kessels, A.G.H.; Kleijnen, J. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. Br. Med. J., 1996, 313, 321-325.
21. Barnes, J.N.; Williams, A.J.; Tomson, M.J.F.; Toseland, P.A.; Goodwin, F.J. Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. Br. Med. J., 1985, 290, 740-742.
22. Davies, K.N.; Castleden, C.M; McBurney, A.; Jagger, C. The effect of ageing on the pharmacokinetics of dihydrocodeine. Eur. J. Clin. Pharmacol., 1989, 37, 375-379.
23. Park, G.R.; Shelly, M.P.; Quinn, K.; Roberts, P. Dihydrocodeine-a reversible cause of renal failure? Eur. J. Anaesthesiol., 1989, 6, 303-314. (Pubitemid 19183806)
24. Barnes, J.M.; Goodwin, F.J. Dihydrocodeine narcosis in renal failure. Br. Med. J., 1983, 286, 438-439.
25. Palmer, R.N.; Eade, O.E.; O'Shea, P.J.; Cuthbert, M.F.; Lond, M.B. Incidence of unwanted effects of dihydrocodeine bitartrate in healthy volunteers. Lancet, 1966, 620-621.
26. Freye, E.; Baranowski, J.; Latasch, L. Dose-related Effects of Controlled Release Dihydrocodeine on Oro-Cecal Transit and Pupillary Light Reflex. Arzneimittelforschung, 2001, 51, 60-66.
27. Kamei, J.; Kasuya, Y. Antitussive effects of Ca2+ channel antagonists. Eur. J. Pharmacol., 1992, 212, 61-66.
28. Kamei, J.; Mori, T.; Kasuya, Y. Effects of L-tryptophan on the effects of antitussives. J. Pharmacobiodyn., 1990, 13, 231-237.
29. Kamei, J.; Morita, K.; Ohsava, M.; Onodera, K. Effects of epinastine on the antitussive and rewarding effects of dihydrocodeine in mice. Methods. Find. Exp. Clin. Pharmacol., 1999, 21, 663-668. (Pubitemid 30090307)
30. Suzuki, T.; Masukawa, Y.; Misawa, M. Drug interactions in the reinforcing effects of over-the-counter cough syrups. Psychopharmacology, 1990, 102, 438-442. (Pubitemid 20379496)
31. Goldmeyer, D.; Lamba, H. Prolonged erections produced by dihydrocodeine and sildanafil. Br. Med. J., 2002, 324, 1555. (Pubitemid 34713133)
32. Spina, E.; de Leon, J. Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review. Basic. Clin. Pharmacol. Toxicol., 2007, 100, 4-22.
33. Kostka-Trabka, E.; Woron, J. Izoenzymy cytochromu P450 a problem interakcji lekow. In Interakcje lekow w praktyce klinicznej, Kostka-Trabka, E.; Woron, J.; Eds.; Wydawnictwo Lekarskie PZWL: Warszawa, 2006; pp. 13-24.
34. Desta, Z.; Wu, G.M.; Morocho, A.M.; Flochart, D.A. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug. Matab. Dispos., 2002, 30, 336-343.
35. Spiller, H.A. Persistently elevatad acetaminophen concentrations for two days after an initial four-hour non-toxic concentration. Vet. Hum. Toxicol., 2001, 43, 218-219.
36. McCleane, G.J. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clin. J. Pain., 2003, 19, 200-201.
37. Dobrogowski, J.; Hilgier, M. Kliniczna ocena dzialania DHC Continus u chorych z bolem przewleklym. Wspolcz. Onkol., 2003, 7, 528-534.
38. Zimmermann, M.; Arnau, H.; Hepper, M. Pain treatment with dihydrocodeine slow release. Results of a post marketing surveillance study. Schmerz, 1995, 9, 185-197.
39. Wotherspoon, H.A.; Kenny, G.N.C.; McArdle, C.S. Analgesic efficacy of controlled-release dihydrocodeine. Anaesthesia, 1991, 46, 915-917.
40. Gostick, N. A comparison of the efficacy and adverse effects of controlled release dihydrocodeine and immediate release dihydrocodeine in the treatment of pain in osteoarthritis and chronic back pain. In The Edinburgh Symposium on Pain Control and Medical Education (L'Etang H.: International Congress and Symposium Series No 149); Twycross R. Ed.; Royal Society of Medicine Services: London, New York 1989; pp. 137-143.
41. Baldwin, R.; Craig, D.L.; Cranfield, R.; Grillage, M.; James, I.G.V.; Lyndon, S.; Mandeville, R.P.; Roy, P. A Study in General Practice to Compare the Efficacy and Safety of DHC Continus® TABLETS and Normal Release Dihydrocodeine Tablets in the Control of Moderate to Severe Pain of Osteoarthritis. NAPP Clin. Rep., 377-384.
42. Aitken, H.A.; Clark, E.C.; McArdle, C.S.; Dimitri, W.; Kenny, G.N. Evaluation of two formulations of dihydrocodeine using patient-controlled analgesia. Anaesthesia, 1990, 45, 535-537.
43. Daniel, J.R.; Wilkins, R.D.; Nicholson, P.A. Two comparisons of the analgesic activity of orally administered pentazocine, dihydrocodeine and placebo. Br. J. Anaesth., 1971, 43, 83-80.
44. Masson, A.H.B. Sublingual Buprenorphine Versus Oral Dihydrocodeine in Post-Operative Pain. J. Int. Med. Res., 1981, 9, 506-510.
45. Frank, B., Serpell, M.G., Hughes, J., Matthews, J.N.S., Kapur, D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. Br. Med. J., 2008, 336, 199-201.
46. Lloyd, R.S.; Costello, F.; Eves, M. J.; James, I.G.V.; Miller, A.J. The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. Curr. Med. Res. Opin., 1992, 13, 37-48.
47. Hummel, T.; Kraetsch, H-G.; Lötsch, J.; Hepper, M.; Liefhold, J.; Kobal, G. Analgesic effects of dihydrocodeine and tramadol when administered either in the morning or evening. Chronobiol. Inter., 1995, 12, 62-72.
48. Leppert, W.; Majkowicz, M. Ocena analgezji i objawow niepozadanych tramadolu i dihydrokodeiny o kontrolowanym uwalnianiu u chorych z bolem nowotworowym-na podstawie zmodyfikowanej skali ESAS. Wspolcz. Onkol., 2008, 12, 246-254.
49. Kress, H.G. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur. J. Pain., 2009, 13, 219-230.
50. Dean, M. Opioids in renal failure and dialysis patient. J. Pain. Symptom. Manage., 2004, 28, 497-504.
51. Leppert, W. The role of methadone in cancer pain treatment-a review. Int. J. Clin. Pract., 2009, 63, 1095-1109.
52. Leppert, W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol. Rep., 2009, 61, 978-992.
53. Gasche, Y.; Daali, Y.; Fathi, M; Chiappe, A.; Cottini, S.; Dayer, P.; Desmeules, J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med., 2004, 351, 2827-2831.
54. Stamer, U.; Musshoff, F.; Kobilay, M.; Madea, B.; Hoeft, A.; Stuber, F. Concentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CY2D6 Genotypes. Clin. Pharmacol. Ther., 2007, 82, 41-47.
55. Thompson, C.M.; Wojno, H.; Greiner, E.; May, E.L.; Rice, K.C; Selley, D.E. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated Metabolites at μ- and δ-opioid receptors. J. Pharmacol. Exp. Ther., 2004, 308, 547-554.
56. Leppert, W. Rola analgetykow opioidowych II stopnia drabiny analgetycznej Swiatowej Organizacji Zdrowia w leczeniu bolu nowotworowego. Onkol. Pol., 2006, 9, 145-148